Literature DB >> 12441804

Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.

Annette Oxenius1, David A Price, Sara J Dawson, Huldrych F Günthard, Marek Fischer, Luc Perrin, Elbe Ramirez, Catherine Fagard, Bernard Hirschel, George Scullard, Jonathan N Weber, Angela R McLean, Rodney E Phillips.   

Abstract

BACKGROUND: Virus-specific cellular immune responses mediated by CD4 and CD8 T lymphocytes are thought to be central to the effective control of HIV-1 replication in vivo. However, quantitative correlations between HIV-specific T lymphocyte frequencies and plasma virus load (pVL) have proved difficult to establish in infected human individuals. This most likely reflects the complex interactions between the virus and these immune effector cells in the absence of treatment.
OBJECTIVE: To assess frequencies of HIV-specific T lymphocytes after prolonged suppression of viral replication, i.e., under conditions where the effects of virus on the immune response are standardized and minimized, thereby fixing an important variable in a dynamic multivariate system.
METHODS: HIV-specific CD4 and CD8 T lymphocyte frequencies were measured in 122 individuals after prolonged periods of successful combination antiretroviral therapy (ART) administered during chronic HIV-1 infection.
RESULTS: The residual frequency of both CD4 and CD8 T lymphocytes specific for HIV-1 was inversely related to the pretreatment pVL. This relationship appeared to be non-linear, indicating the presence of a threshold pretreatment pVL level above which HIV-specific CD4 and CD8 T lymphocyte responses could not be maintained when antigenic drive was suppressed. Substantial populations of functional HIV-specific CD4 and CD8 T lymphocytes were generally detectable after prolonged ART only in those individuals with a pretreatment plasma HIV-1 RNA < 100,000 copies/ml.
CONCLUSION: These findings identify a quantitative immune associate of host-virus interactions in established HIV-1 infection. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441804     DOI: 10.1097/00002030-200211220-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.

Authors:  Deborah Persaud; Katherine Luzuriaga; Carrie Ziemniak; Petronella Muresan; Thomas Greenough; Terry Fenton; Amanda Blackford; Kimberly Ferguson; Natalie Neu; Coleen K Cunningham
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

Review 2.  Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Authors:  Bernard J C Macatangay; Charles R Rinaldo
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

3.  Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels.

Authors:  Eli Boritz; Brent E Palmer; Cara C Wilson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  T cell functionality in HIV-1, HIV-2 and dually infected individuals: correlates of disease progression and immune restoration.

Authors:  S Salwe; V Padwal; V Nagar; P Patil; V Patel
Journal:  Clin Exp Immunol       Date:  2019-07-18       Impact factor: 4.330

5.  CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.

Authors:  Eli Boritz; Eric L Rapaport; Thomas B Campbell; John R Koeppe; Cara C Wilson
Journal:  Virology       Date:  2006-12-13       Impact factor: 3.616

6.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Precise identification of a human immunodeficiency virus type 1 antigen processing mutant.

Authors:  Peter Zimbwa; Anita Milicic; John Frater; Thomas J Scriba; Antony Willis; Philip J R Goulder; Tilly Pillay; Huldrych Gunthard; Jonathan N Weber; Hua-Tang Zhang; Rodney E Phillips
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 8.  Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.

Authors:  S D Lawn; R J Wilkinson
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

9.  Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Authors:  Beda Joos; Alexandra Trkola; Marek Fischer; Herbert Kuster; Peter Rusert; Christine Leemann; Jürg Böni; Annette Oxenius; David A Price; Rodney E Phillips; Joseph K Wong; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.